Estudios primarios incluidos en esta revisión sistemática

loading
37 articles (37 Referencias) loading Revertir Estudificar

Estudio primario

No clasificado

Revista Journal of clinical pharmacology
Año 2011
Cargando información sobre las referencias

Estudio primario

No clasificado

Revista Clinical neuropharmacology
Año 2011
Cargando información sobre las referencias
OBJECTIVES: Disulfiram is effective in relapse prevention in alcoholism. However, the optimal therapeutic aftercare regimen for patients is still unclear, and disulfiram is associated with numerous adverse events. Also, it is not clear if supervised long-term disulfiram treatment is safe and sufficiently efficient in the long run. METHODS: We evaluated the clinical outcome data of 10 alcohol-dependent patients who underwent supervised treatment with disulfiram for more than 50 weeks. RESULTS: Seven of 10 patients remained completely abstinent during the supervised disulfiram therapy for a mean (SD) period of 70.1 ± 23.5 months. For the 3 patients with relapse, the first relapse occurred after a mean (SD) of 34.7 ± 15.5 months. Liver enzymes in the blood decreased markedly under treatment with disulfiram. The overall tolerability was considered to be high; only dizziness and fatigue were observed in 4 patients in the initial phase of the therapy. No serious adverse events were recorded. CONCLUSIONS: Although case observations should be interpreted with caution, the present results suggest that disulfiram is safe and efficient in supervised long-term treatment of alcohol-dependent patients.

Estudio primario

No clasificado

Autores Cho YN , Lyoo CH , Lee MS
Revista Movement disorders : official journal of the Movement Disorder Society
Año 2011
Cargando información sobre las referencias

Estudio primario

No clasificado

Revista Journal of neurology
Año 2011
Cargando información sobre las referencias

Estudio primario

No clasificado

Revista Drug and alcohol dependence
Año 2011
Cargando información sobre las referencias
<b>BACKGROUND: </b>A majority of cocaine addicts have a comorbid alcohol use disorder. Previous studies demonstrated efficacy of disulfiram in the treatment of cocaine dependence among patients with comorbid alcohol use disorder or opioid dependence. However, the cardiac risks of a disulfiram-ethanol reaction (DER) in individuals who drink, when coupled with the cardiac effects of cocaine, could result in significant toxicity or lethality due to the 3-way drug interaction.<b>AIMS: </b>This study examined the safety of combining cocaine (30 mg i.v.) and ethanol (0.4 g/kg i.v.) in disulfiram-treated (0, 250, and 500 mg/d, p.o.) cocaine-dependent research volunteers.<b>RESULTS: </b>The results showed that disulfiram did not enhance the cardiovascular effects of cocaine and may have reduced the subjective high from cocaine. In contrast, ethanol produced adverse ECG changes including QTc prolongation and a DER consisting of hypotension, tachycardia, nausea, and flushing in disulfiram-treated subjects. The severity of the DER was related to disulfiram dose and the trial with 500 mg/d was stopped prematurely due to safety concerns. The DER-related hypotension and tachycardia seen with ethanol infusion alone in disulfiram-treated subjects, was not exacerbated when combined with cocaine. In fact, cocaine tended to counteract the ethanol-related hypotension though it did exacerbate the tachycardia in two of seven subjects.<b>CONCLUSIONS: </b>Though conclusions are limited by the moderate doses of cocaine, ethanol, and disulfiram tested, the data do suggest that the risks of the moderate use of cocaine and ethanol in individuals treated with moderate doses of disulfiram (≤ 250 mg/d) may not be as problematic as some may assume.

Estudio primario

No clasificado

Revista Journal of Cardiology Cases
Año 2010
Cargando información sobre las referencias

Estudio primario

No clasificado

Revista Journal of neurology, neurosurgery, and psychiatry
Año 2010
Cargando información sobre las referencias

Estudio primario

No clasificado

Revista Progress in neuro-psychopharmacology & biological psychiatry
Año 2010
Cargando información sobre las referencias

Estudio primario

No clasificado

Autores Mutschler J , Diehl A , Kiefer F
Revista Journal of clinical psychopharmacology
Año 2009
Cargando información sobre las referencias

Estudio primario

No clasificado

Autores Bae JS
Revista Journal of voice : official journal of the Voice Foundation
Año 2009
Cargando información sobre las referencias
Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy. A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness. She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state. A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy. Laryngeal electromyography (thyroarytenoid muscle) showed ample denervation potentials. Laryngoscopy revealed asymmetric vocal fold movements during phonation. Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer. This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.